Bovine Respiratory Disease Treatment Market - Growth, Trends, and Forecast (2019-2024)

The market is segmented by Treatment Type (Vaccines, Antibiotics, NSAIDs, Immunomodulators, and Other Treatment Types), by Disease Type, and Geography

Market Snapshot

bovine respiratory disease treatment market
Study Period:

2016-2024

Base Year:

2018

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

11.5%

Key Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

The increasing consumption of beef and rising population are major factors that are driving the market studied. The increase in beef consumption is due to the rising population and increasing disposable income, across the world. Bovine Respiratory Disease (BRD) has a negative impact on both the dairy and beef industries, due to calf mortality, additional labor costs, and treatment expenses.

In addition, BRD adversely affects the reproductive performance, growth, and lifespan of cattle. Hence, there is a huge necessity for BRD treatment in the market. Moreover, to meet the increasing demand for beef, most of the countries in the world are increasing the production of cattle meat. The rising demand for beef, coupled with increased production of the same, leads to a growing emphasis on BRD treatment.

There are certain complexities that are associated with the diagnosis of the BRD. Animals suffering from BRD often show signs of depression, weight loss, cough, mucopurulent or purulent nasal discharge, fever, increased respiratory rate, and abnormal pulmonary sound on auscultation. The presumptive diagnosis after a physical examination is, however, difficult, owing to the similarities of clinical signs and variation of possible bacteria. Hence, the complex diagnostic procedure is restricting market growth.

Scope of the Report

Bovine Respiratory Disease (BRD) is the general term used for respiratory diseases in cattle or bovines. BRD is usually caused by both viral and bacterial pathogens and can affect the lower respiratory tract and upper respiratory tract. 

By Treatment Type
Vaccines
Antibiotics
NSAIDs
Immunomodulators
Other Treatment Tyes
By Diseases Type
Lower Respiratory Tract Infections
Upper Respiratory Tract Infections
Diphtheria
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Vaccines are Expected to Register Highest CAGR Over the Forecast Period

A vast range of bovine vaccines is available in the market for dairy and beef cattle to provide them protection against serious respiratory diseases. Klebsiella is a widespread pathogen which has been found to hamper dairy operations and has cost producers noteworthy losses. AgriLabs manufactured the first vaccine to prevent mastitis caused by Klebsiella pneumoni and this vaccine (KLEBVax SRP) is currently commercially available as announced on 23 July 2018 by the company. Hence, this cattle vaccine is expected to improve its market share in the coming years.

In April 2018, VIDO - InterVac announced about the development of a new vaccine to protect cattle in Africa against contagious bovine pleuropneumonia (CBPP), an infectious lung disease which has affected the livelihoods of approximately 24 million small-scale cattle farmers in Africa, causing more than USD 60 million yearly in losses. This type of research has brought about significant growth in the bovine vaccine market in developing regions.

Hence, it is believed that due to the availability of the vaccines and the company's focus on coming up with more of them, the vaccine segment will dominate the market with a highest CAGR over the forecast period.

bovine respiratory disease treatment market

To understand key trends, Download Sample Report

North America to Dominate the Bovine Respiratory Disease Treatment Market

North America dominates the bovine respiratory disease treatment market, owing to the increasing domestic production, consumption, and export of bovine meat. According to the estimates of the United Nations Food and Agricultural Organization (UNFAO) for the year 2015-2016, America produced approximately 30 million tonnes of the meat, and it is expected to rise, owing to a rise in population. BRD is the most common endemic disease among North American feedlot cattle. According to the estimates of the Beef Cattle Research Council, BRD accounts for 65-80% of the morbidity and 45-75% of the mortality in the feedlots. Thus, the increasing consumption and production of bovine meat and rising cases of BRD are expected to propel the growth of the bovine respiratory disease treatment market in the region, over the forecast period.

bovine respiratory disease treatment market

To understand geography trends, Download Sample Report

Competitive Landscape

The market for bovine respiratory disease treatment is moderately competitive. There are few global players that are holding more of the market share. However, with the rising focus on veterinary health, various small companies are also coming up with the novel therapeutics. Hence, it is expected that these companies will hold a substantial share of the market in the coming future.

Major Players

  1. Bayer AG
  2. Ceva
  3. Boehringer Ingelheim GmbH
  4. Elanco
  5. Virbac

* Complete list of players covered available in the table of contents below

bovine respiratory disease treatment market

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Incidence of BRD (Bovine Respiratory Diseases)

      2. 4.2.2 Increasing Consumption of Beef

      3. 4.2.3 Changing Environmental Factors

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Awareness about the Treatment of BRD in Developing and Underdeveloped Countries

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Treatment Type

      1. 5.1.1 Vaccines

      2. 5.1.2 Antibiotics

      3. 5.1.3 NSAIDs

      4. 5.1.4 Immunomodulators

      5. 5.1.5 Other Treatment Tyes

    2. 5.2 By Diseases Type

      1. 5.2.1 Lower Respiratory Tract Infections

      2. 5.2.2 Upper Respiratory Tract Infections

      3. 5.2.3 Diphtheria

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 US

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 UK

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Bayer AG

      2. 6.1.2 Bimeda

      3. 6.1.3 Boehringer Ingelheim GmbH

      4. 6.1.4 Ceva

      5. 6.1.5 Elanco

      6. 6.1.6 Merck & Co. Inc.

      7. 6.1.7 Vetoquinol

      8. 6.1.8 Virbac

      9. 6.1.9 Zoetis

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please Enter a Valid Message!


Complete your payment details below

Shipping & Billing Information

Payment Information